PPD02.03 Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Analysis of All Patients From VISION Cohorts A and C

M.C. Garassino,M. Thomas, E. Felip,H. Sakai,X. Le, R. Veillon,E.F. Smit,J. Mazieres,A.B. Cortot, J. Raskin,S. Viteri,J. Chih-Hsin Yang,M.-J. Ahn,Y.-L. Wu, R. Ma, J. Zhao, A. O'Brate, K. Berghoff,R. Bruns, G. Otto,P. Paik

Journal of Thoracic Oncology（2023）

引用 0|浏览10

暂无评分

摘要

Tepotinib, a MET TKI, is approved for the treatment of METex14 skipping NSCLC. Here, we report analysis of all patients with METex14 skipping in the Phase II VISION study (Cohort A: >2-years’ follow-up; confirmatory Cohort C: >9-months’ follow-up); data cut-off February 20, 2022. Previously presented at WCLC 2022.

查看译文

关键词

nsclc,metex14,met exon

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要